Clinical Trials Directory

Trials / Completed

CompletedNCT01001806

A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification

A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
126 (actual)
Sponsor
Frank A. Bucci, Jr., M.D. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac. Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery. Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses. At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected. The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.

Conditions

Interventions

TypeNameDescription
DRUGKetorolac Tromethamine 0.45%One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
DRUGbromfenac 0.09%One day pre operative 1 drop BID then 3 doses pre op day of surgery
DRUGnepafenac 0.1%One drop BID, 1 day pre operative and then 3 doses the day of surgery

Timeline

Start date
2009-10-01
Primary completion
2009-12-01
Completion
2010-01-01
First posted
2009-10-27
Last updated
2011-10-03
Results posted
2011-08-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01001806. Inclusion in this directory is not an endorsement.